No Data
Optimistic Buy Rating for NewAmsterdam Pharma Driven by Promising Clinical Trials and Innovative Lipid-Lowering Therapies
NewAmsterdam Pharma Company N.V. (NASDAQ:NAMS) Shares Could Be 46% Below Their Intrinsic Value Estimate
Leerink Partners Maintains NewAmsterdam Pharma(NAMS.US) With Buy Rating, Maintains Target Price $42
NewAmsterdam Pharma Reports Strong Q3 and Trial Progress
Scotiabank Maintains NewAmsterdam Pharma(NAMS.US) With Buy Rating, Maintains Target Price $35
RBC Capital Maintains NewAmsterdam Pharma(NAMS.US) With Buy Rating, Maintains Target Price $31
No Data
No Data